C-TRACT Trial: Venous Stenting for Post-Thrombotic Syndrome

This episode breaks down the landmark C-TRACT trial (NEJM 2026), a phase 3 randomized study testing whether iliac vein stenting plus enhanced antithrombotic therapy actually improves outcomes in patients with moderate-to-severe post-thrombotic syndrome (PTS). The Clinical Question: Does restoring iliac venous outflow with stenting meaningfully improve symptoms and quality of life? Result: Endovascular therapy significantly improved symptom burden, with a meaningful reduction in VCSS severity and a striking 14.5-point improvement in quality-of-life scores. Mechanical Win: Stent thrombosis was remarkably low at just 0.9%, reinforcing the importance of rigorous inflow assessment, mandatory IVUS, and aggressive stent sizing in chronic venous disease. Trade-Off: Bleeding complications were substantially higher in the intervention arm (11.6% vs. 3.6%), largely driven by prolonged dual antithrombotic therapy rather than the procedure itself. Bottom Line: For carefully selected PTS patients with good inflow and significant iliac obstruction, iliac vein stenting can deliver meaningful symptom relief, but success depends heavily on patient selection, IVUS-guided technique, and thoughtful post-op management.Tune in to learn which post-thrombotic patients actually benefit from venous stenting—and where the limits of the “open vein hypothesis” begin.